bevacizumab
Pronunciation: /bɛvəˈsɪzəmæb/
A monoclonal antibody targeting VEGF, commonly used in recurrent glioblastoma with specific imaging considerations.
Full Definition
Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), used primarily in recurrent glioblastoma treatment. While it can produce dramatic radiographic responses by reducing tumor-associated edema and contrast enhancement, it may not translate to improved overall survival. Editors must understand bevacizumab's unique effects on imaging interpretation, the concept of non-enhancing tumor progression, and the specific safety profile including risks of hemorrhage, thromboembolism, and wound healing complications.
Usage
Usage note: Include brand name 'Avastin' when appropriate; specify that radiographic response may not correlate with survival benefit.
In Context
- "Bevacizumab therapy resulted in significant reduction of contrast enhancement and peritumoral edema." — Radiology treatment response report
- "Patients receiving bevacizumab require careful monitoring for hemorrhagic complications." — Safety monitoring protocol